Zynex ZYXI shares are trading higher on Monday after H.C. Wainwright & Co upgraded the stock from Neutral to Buy and announced a price target of $25 per share.
Zynex is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products.
The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. It also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development.
The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave, Non-Invasive Blood Volume Monitor and others.
Zynex shares were trading up 7.04% at $16.58 on Monday during the time of publication. The stock has a 52-week high of $29.73 and a 52-week low of $7.51.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
